Integrating the microneedles with carboplatin to facilitate the therapeutic effect of radiotherapy for skin cancers

Biomater Adv. 2022 Oct:141:213113. doi: 10.1016/j.bioadv.2022.213113. Epub 2022 Sep 6.

Abstract

In most skin cancer patients, excisional surgery is required to remove tumorous tissue. However, the risk of locoregional recurrence after surgery alone is relatively high, particularly for a locally advanced stage of melanoma. Therefore, additional adjuvant treatments, such as radiotherapy, can be used after surgery to inhibit recurrent melanoma after surgical removal. To enhance local radiotherapy, we present the combined X-ray radiation and radiosensitizers (carboplatin) through microneedles (MNs) to treat melanoma. The MNs could be beneficial to precisely delivering carboplatin into the sub-epidermal layer of the melanoma region and alleviate patients' fear and discomfort during the drug administration compared to the traditional local injection. The carboplatin was loaded into the tips of dissolving gelatin MNs (carboplatin-MNs) through the molding method. The results show gelatin MNs have sufficient mechanical strength and can successfully administer carboplatin into the skin. Both in vitro and in vivo studies suggest that carboplatin can enhance radiotherapy in melanoma treatment. With a combination of radiotherapy and carboplatin, the inhibition effect of carboplatin delivered into the B16F10 murine melanoma model through MNs administration (1.2 mg/kg) is equivalent to that through an intravenous route (5 mg/kg). The results demonstrate a promise of combined carboplatin and X-ray radiation treatment in treating melanoma by MNs administration.

Keywords: Carboplatin; Melanoma; Microneedles; Radiosensitizer.

MeSH terms

  • Administration, Cutaneous
  • Animals
  • Carboplatin / therapeutic use
  • Gelatin
  • Humans
  • Melanoma* / drug therapy
  • Mice
  • Needles
  • Skin Neoplasms* / drug therapy

Substances

  • Gelatin
  • Carboplatin